285 related articles for article (PubMed ID: 32397368)
1. Two Birds with One Stone: NFAT1-MDM2 Dual Inhibitors for Cancer Therapy.
Wang W; Zafar A; Rajaei M; Zhang R
Cells; 2020 May; 9(5):. PubMed ID: 32397368
[TBL] [Abstract][Full Text] [Related]
2. Experimental Therapy of Advanced Breast Cancer: Targeting NFAT1-MDM2-p53 Pathway.
Qin JJ; Wang W; Zhang R
Prog Mol Biol Transl Sci; 2017; 151():195-216. PubMed ID: 29096894
[TBL] [Abstract][Full Text] [Related]
3. MDM2-NFAT1 dual inhibitor, MA242: Effective against hepatocellular carcinoma, independent of p53.
Wang W; Cheng JW; Qin JJ; Hu B; Li X; Nijampatnam B; Velu SE; Fan J; Yang XR; Zhang R
Cancer Lett; 2019 Sep; 459():156-167. PubMed ID: 31181320
[TBL] [Abstract][Full Text] [Related]
4. Discovery and Characterization of Dual Inhibitors of MDM2 and NFAT1 for Pancreatic Cancer Therapy.
Wang W; Qin JJ; Voruganti S; Nijampatnam B; Velu SE; Ruan KH; Hu M; Zhou J; Zhang R
Cancer Res; 2018 Oct; 78(19):5656-5667. PubMed ID: 30217928
[TBL] [Abstract][Full Text] [Related]
5. Inulanolide A as a new dual inhibitor of NFAT1-MDM2 pathway for breast cancer therapy.
Qin JJ; Wang W; Sarkar S; Voruganti S; Agarwal R; Zhang R
Oncotarget; 2016 May; 7(22):32566-78. PubMed ID: 27105525
[TBL] [Abstract][Full Text] [Related]
6. Inhibiting NFAT1 for breast cancer therapy: New insights into the mechanism of action of MDM2 inhibitor JapA.
Qin JJ; Wang W; Voruganti S; Wang H; Zhang WD; Zhang R
Oncotarget; 2015 Oct; 6(32):33106-19. PubMed ID: 26461225
[TBL] [Abstract][Full Text] [Related]
7. Transcription factor NFAT1 activates the mdm2 oncogene independent of p53.
Zhang X; Zhang Z; Cheng J; Li M; Wang W; Xu W; Wang H; Zhang R
J Biol Chem; 2012 Aug; 287(36):30468-76. PubMed ID: 22787160
[TBL] [Abstract][Full Text] [Related]
8. Identification of lineariifolianoid A as a novel dual NFAT1 and MDM2 inhibitor for human cancer therapy.
Qin JJ; Sarkar S; Voruganti S; Agarwal R; Wang W; Zhang R
J Biomed Res; 2016 Jul; 30(4):322-33. PubMed ID: 27533941
[TBL] [Abstract][Full Text] [Related]
9. DIMP53-1: a novel small-molecule dual inhibitor of p53-MDM2/X interactions with multifunctional p53-dependent anticancer properties.
Soares J; Espadinha M; Raimundo L; Ramos H; Gomes AS; Gomes S; Loureiro JB; Inga A; Reis F; Gomes C; Santos MMM; Saraiva L
Mol Oncol; 2017 Jun; 11(6):612-627. PubMed ID: 28296148
[TBL] [Abstract][Full Text] [Related]
10. MDM2-p53 Interaction Inhibitors: The Current State-of-Art and Updated Patent Review (2010-Present).
Rusiecki R; Witkowski J; Jaszczewska-Adamczak J
Recent Pat Anticancer Drug Discov; 2019; 14(4):324-369. PubMed ID: 31642413
[TBL] [Abstract][Full Text] [Related]
11. Medicinal Chemistry Strategies to Disrupt the p53-MDM2/MDMX Interaction.
Lemos A; Leão M; Soares J; Palmeira A; Pinto M; Saraiva L; Sousa ME
Med Res Rev; 2016 Sep; 36(5):789-844. PubMed ID: 27302609
[TBL] [Abstract][Full Text] [Related]
12. Resistance acquisition to MDM2 inhibitors.
Cinatl J; Speidel D; Hardcastle I; Michaelis M
Biochem Soc Trans; 2014 Aug; 42(4):752-7. PubMed ID: 25109953
[TBL] [Abstract][Full Text] [Related]
13. p53-Mdm2 Interaction Inhibitors as Novel Nongenotoxic Anticancer Agents.
Nayak SK; Khatik GL; Narang R; Monga V; Chopra HK
Curr Cancer Drug Targets; 2018; 18(8):749-772. PubMed ID: 28669344
[TBL] [Abstract][Full Text] [Related]
14. MDM2/X inhibitors under clinical evaluation: perspectives for the management of hematological malignancies and pediatric cancer.
Tisato V; Voltan R; Gonelli A; Secchiero P; Zauli G
J Hematol Oncol; 2017 Jul; 10(1):133. PubMed ID: 28673313
[TBL] [Abstract][Full Text] [Related]
15. MDM2 Inhibitors for Cancer Therapy: The Past, Present, and Future.
Wang W; Albadari N; Du Y; Fowler JF; Sang HT; Xian W; McKeon F; Li W; Zhou J; Zhang R
Pharmacol Rev; 2024 May; 76(3):414-453. PubMed ID: 38697854
[TBL] [Abstract][Full Text] [Related]
16. Targeting the p53-MDM2 pathway for neuroblastoma therapy: Rays of hope.
Zafar A; Wang W; Liu G; Xian W; McKeon F; Zhou J; Zhang R
Cancer Lett; 2021 Jan; 496():16-29. PubMed ID: 33007410
[TBL] [Abstract][Full Text] [Related]
17. Natural product MDM2 inhibitors: anticancer activity and mechanisms of action.
Qin JJ; Nag S; Voruganti S; Wang W; Zhang R
Curr Med Chem; 2012; 19(33):5705-25. PubMed ID: 22830335
[TBL] [Abstract][Full Text] [Related]
18. Resistance mechanisms to inhibitors of p53-MDM2 interactions in cancer therapy: can we overcome them?
Haronikova L; Bonczek O; Zatloukalova P; Kokas-Zavadil F; Kucerikova M; Coates PJ; Fahraeus R; Vojtesek B
Cell Mol Biol Lett; 2021 Dec; 26(1):53. PubMed ID: 34911439
[TBL] [Abstract][Full Text] [Related]
19. Targeting MDM2-p53 interaction for cancer therapy: are we there yet?
Nag S; Zhang X; Srivenugopal KS; Wang MH; Wang W; Zhang R
Curr Med Chem; 2014; 21(5):553-74. PubMed ID: 24180275
[TBL] [Abstract][Full Text] [Related]
20. The role of p53 in cancer drug resistance and targeted chemotherapy.
Hientz K; Mohr A; Bhakta-Guha D; Efferth T
Oncotarget; 2017 Jan; 8(5):8921-8946. PubMed ID: 27888811
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
